Pharma Deals Review, Vol 2004, No 49 (2004)

Font Size:  Small  Medium  Large

CuraGen Licenses TopoTarget’s HDAC Inhibitor

Business Review Editor

Abstract


CuraGen acquired exclusive rights to develop and commercialise TopoTarget’s PXD101 (Phase I treatment for solid and hematological cancers) in Europe.
TopoTarget will receive more than US$51 M for PDX101 and reciprocal royalties from CuraGen.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.